fenebrutinib + itraconazole

GDC-0853 (fenebrutinib) is an orally administered, highly selective, noncovalent, and reversible small molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Genentech. BTK is a cytoplasmic tyrosine kinase that plays a critical role in B-cell and myeloid cell signaling pathways, which are implicated in the pathogenesis of various autoimmune and inflammatory diseases. The specific combination of GDC-0853 and itraconazole refers to a Phase 1 drug-drug interaction study designed to evaluate the effect of itraconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of GDC-0853 in healthy volunteers. While GDC-0853 is being advanced in Phase 3 clinical trials for multiple sclerosis and has been studied in Phase 2 for rheumatoid arthritis, systemic lupus erythematosus, and chronic spontaneous urticaria, the combination with itraconazole is used for clinical pharmacology assessment rather than as a therapeutic product.

Other names

GDC-0853 + itraconazolefenebrutinib + itraconazole